Matches in SemOpenAlex for { <https://semopenalex.org/work/W4253912017> ?p ?o ?g. }
- W4253912017 abstract "Background Neovascular age‐related macular degeneration (AMD) is associated with rapid vision loss due to choroidal neovascularization (CNV), leakage, and scarring. Steroids have gained attention in their role for the treatment of neovascular AMD for their antiangiogenic and anti‐inflammatory properties. Objectives This review aims to examine effects of steroids with antiangiogenic properties in the treatment of neovascular AMD. Search methods We searched for trials in CENTRAL, MEDLINE, EMBASE, and LILACS on 2 October 2006. Selection criteria We included randomised controlled clinical trials of intra‐ and peri‐ocular steroids in people diagnosed with neovascular AMD. Data collection and analysis Review authors extracted the data and assessed trial quality independently. We did not pool data since the included studies evaluated difference comparisons. Main results We report the risk of losing three or more lines vision at 12 months ‐ vision loss. One trial (139 people randomized) reported that a single dose of intravitreal triamcinolone (n = 75) (4 mg) had no significant effect on the risk of vision loss compared to placebo (n = 76). (Risk ratio vision loss 0.97, 95% confidence interval (CI) 0.74 to 1.26). Eyes treated with triamcinolone were more likely to develop cataracts and experience increased intraocular pressure (IOP) compared to untreated eyes. One trial (128 people randomized) reported the effects of anecortave acetate (3 mg (n = 32), 15 mg (n = 33) or 30 mg (n = 33) single dose with retreatment every six months if indicated) compared to placebo (n = 30). Risk ratio vision loss 0.80 (95% CI 0.45 to 1.45) in the 3 mg group, 0.45 (95% CI 0.21 to 0.97) in the 15 mg group and 0.91 (95% CI 0.52 to 1.58) in the 30 mg group. Side effects were similar in all treatment groups with the anecortave group having a slightly higher incidence of foreign body sensation compared to placebo. There was a high loss to follow‐up. The final analysis may have been subject to selection bias as participants who were not selected for retreatment, possibly with worsening disease, were excluded. There was also a possibility of type I error due to multiple statistical comparisons. The sample size was estimated on the basis of a single 2‐way comparison but three 2‐way comparisons were analysed and presented. One trial reported that anecortave acetate (n = 263) (15 mg administered at beginning of study and six months) gave similar results to photodynamic therapy (n = 267) (risk ratio vision loss 1.08, 95% CI 0.91 to 1.29). Authors' conclusions Overall there is weak evidence as to the benefits and harms of steroids with antiangiogenic properties for treating neovascular AMD with only three published trials of variable quality. Intravitreal triamcinolone injection for neovascular AMD does not appear to prevent severe vision loss and is associated with increased IOP and higher risk of cataract formation. Anecortave acetate 15 mg may have a mild benefit in stabilizing vision, but further better quality evidence is needed. The role of steroids in combination with other treatment modalities is yet to be determined." @default.
- W4253912017 created "2022-05-12" @default.
- W4253912017 creator A5004144152 @default.
- W4253912017 creator A5036968578 @default.
- W4253912017 creator A5087655863 @default.
- W4253912017 date "2007-10-17" @default.
- W4253912017 modified "2023-09-23" @default.
- W4253912017 title "Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration" @default.
- W4253912017 cites W1479998022 @default.
- W4253912017 cites W1495055821 @default.
- W4253912017 cites W1510328004 @default.
- W4253912017 cites W1558479151 @default.
- W4253912017 cites W1601975653 @default.
- W4253912017 cites W1976638542 @default.
- W4253912017 cites W1981362657 @default.
- W4253912017 cites W1986531295 @default.
- W4253912017 cites W1992087811 @default.
- W4253912017 cites W1994515616 @default.
- W4253912017 cites W2000723076 @default.
- W4253912017 cites W2060721372 @default.
- W4253912017 cites W2075634939 @default.
- W4253912017 cites W207576288 @default.
- W4253912017 cites W2092816889 @default.
- W4253912017 cites W2094310573 @default.
- W4253912017 cites W2099490431 @default.
- W4253912017 cites W2108762814 @default.
- W4253912017 cites W2122902311 @default.
- W4253912017 cites W2125781987 @default.
- W4253912017 cites W2153232819 @default.
- W4253912017 cites W2159723361 @default.
- W4253912017 cites W2165265638 @default.
- W4253912017 cites W2168163081 @default.
- W4253912017 cites W2170353976 @default.
- W4253912017 cites W2326455829 @default.
- W4253912017 cites W2340705045 @default.
- W4253912017 cites W2416776471 @default.
- W4253912017 cites W3202352366 @default.
- W4253912017 cites W4210258459 @default.
- W4253912017 cites W4230906879 @default.
- W4253912017 cites W4235244632 @default.
- W4253912017 cites W4246295494 @default.
- W4253912017 cites W4255079092 @default.
- W4253912017 cites W4297900156 @default.
- W4253912017 cites W4300126839 @default.
- W4253912017 doi "https://doi.org/10.1002/14651858.cd005022.pub2" @default.
- W4253912017 hasPublicationYear "2007" @default.
- W4253912017 type Work @default.
- W4253912017 citedByCount "5" @default.
- W4253912017 countsByYear W42539120172012 @default.
- W4253912017 countsByYear W42539120172013 @default.
- W4253912017 crossrefType "reference-entry" @default.
- W4253912017 hasAuthorship W4253912017A5004144152 @default.
- W4253912017 hasAuthorship W4253912017A5036968578 @default.
- W4253912017 hasAuthorship W4253912017A5087655863 @default.
- W4253912017 hasBestOaLocation W42539120172 @default.
- W4253912017 hasConcept C118487528 @default.
- W4253912017 hasConcept C126322002 @default.
- W4253912017 hasConcept C141071460 @default.
- W4253912017 hasConcept C142724271 @default.
- W4253912017 hasConcept C168563851 @default.
- W4253912017 hasConcept C204787440 @default.
- W4253912017 hasConcept C27081682 @default.
- W4253912017 hasConcept C2776403814 @default.
- W4253912017 hasConcept C2778903070 @default.
- W4253912017 hasConcept C2780225610 @default.
- W4253912017 hasConcept C2781359195 @default.
- W4253912017 hasConcept C44249647 @default.
- W4253912017 hasConcept C535046627 @default.
- W4253912017 hasConcept C71924100 @default.
- W4253912017 hasConceptScore W4253912017C118487528 @default.
- W4253912017 hasConceptScore W4253912017C126322002 @default.
- W4253912017 hasConceptScore W4253912017C141071460 @default.
- W4253912017 hasConceptScore W4253912017C142724271 @default.
- W4253912017 hasConceptScore W4253912017C168563851 @default.
- W4253912017 hasConceptScore W4253912017C204787440 @default.
- W4253912017 hasConceptScore W4253912017C27081682 @default.
- W4253912017 hasConceptScore W4253912017C2776403814 @default.
- W4253912017 hasConceptScore W4253912017C2778903070 @default.
- W4253912017 hasConceptScore W4253912017C2780225610 @default.
- W4253912017 hasConceptScore W4253912017C2781359195 @default.
- W4253912017 hasConceptScore W4253912017C44249647 @default.
- W4253912017 hasConceptScore W4253912017C535046627 @default.
- W4253912017 hasConceptScore W4253912017C71924100 @default.
- W4253912017 hasLocation W42539120171 @default.
- W4253912017 hasLocation W42539120172 @default.
- W4253912017 hasLocation W42539120173 @default.
- W4253912017 hasOpenAccess W4253912017 @default.
- W4253912017 hasPrimaryLocation W42539120171 @default.
- W4253912017 hasRelatedWork W1033105454 @default.
- W4253912017 hasRelatedWork W1035498673 @default.
- W4253912017 hasRelatedWork W1229783908 @default.
- W4253912017 hasRelatedWork W1989880875 @default.
- W4253912017 hasRelatedWork W2037500032 @default.
- W4253912017 hasRelatedWork W2048988714 @default.
- W4253912017 hasRelatedWork W2377851881 @default.
- W4253912017 hasRelatedWork W2993317451 @default.
- W4253912017 hasRelatedWork W995924308 @default.
- W4253912017 hasRelatedWork W2528656035 @default.
- W4253912017 isParatext "false" @default.
- W4253912017 isRetracted "false" @default.